文献速递临床试验与 GCP流行病学与生物统计

社区主导消除疟疾(CoRE):评估社区层面反应性焦点给药降低赞比亚南部省恶性疟原虫感染率与发病率效果的社区随机对照试验方案

Community-led Responses for Elimination (CoRE): a study protocol for a community randomized controlled trial assessing the effectiveness of community-level, reactive focal drug administration for reducing Plasmodium falciparum infection prevalence and incidence in Southern Province, Zambia.
PubMed 文献 · Trials · 2017-11-02

赞比亚南部省疟疾传播水平低、病媒控制覆盖高。本研究采用社区随机对照试验,将16个卫生设施服务区随机分配至连续2年反应性焦点给药(RFDA,双氢青蒿素哌喹)组或反应性焦点检测治疗(RFTAT,蒿甲醚苯芴醇)对照组,评估对恶性疟原虫患病率和发病率的影响。主要结局为干预后调查的疟疾血清阳性率(n=4800名1月至5岁以下儿童)和差值中的差值分析的疟疾发病率,把握度可检测约65%的相对下降。

要点

  • RFDA使用双氢青蒿素哌喹(DHAP)对比RFTAT使用蒿甲醚苯芴醇(AL)标准治疗。
  • 反应性病例检测由确诊疟疾触发,社区卫生工作者在指示病例确诊后7天内于140米半径内实施。
  • 主要结局为干预后儿童血清阳性率调查和常规被动病例检测的发病率差值中的差值分析。

核心结论

  • 研究旨在量化RFDA联合DHAP相较于RFTAT联合AL(标准治疗)在降低恶性疟原虫患病率和发病率方面的相对有效性。

研究设计与样本

  • 在赞比亚南部省四个疟疾传播低、病媒控制覆盖高的地区开展社区随机对照试验,纳入16个卫生设施服务区。
  • 干预为连续2年全年常规RFDA,对照为连续2年全年常规RFTAT,由社区卫生工作者在指示病例确诊后7天内于140米半径内实施反应性响应。
  • 部分反应性响应进行90天纵向随访以检查再感染率;主要结局包括干预后疟疾血清阳性率调查(n=4800名1月至5岁以下儿童)和基于卫生设施常规被动病例检测的疟疾发病率差值中的差值分析。
  • 研究把握度可检测干预组相对对照组主要结局约65%的相对下降。

关键数值与推荐

  • 反应性病例检测由显微镜检查或快速诊断试验在任何政府卫生设施确诊的疟疾病例触发。
  • 反应性响应在指示病例确诊日期后7天内实施,范围为指示病例家庭周围140米半径。
  • 主要结局把握度可检测约65%的相对下降。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 统计把握度仅能检测主要结局65%的下降。
  • 存在潜在污染可能稀释干预效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Zambia is pushing for, and has made great strides towards, the elimination of malaria transmission in Southern Province. Reactive focal test and treat (RFTAT) using rapid diagnostic tests and artemether-lumefantrine (AL) has been key in making this progress. Reactive focal drug administration (RFDA) using dihydroartemisinin-piperaquine (DHAP), may be superior in accelerating clearance of the parasite reservoir in humans due to the provision of enhanced chemoprophylactic protection of at-risk populations against new infections. The primary aim of this study is to quantify the relative effectiveness of RFDA with DHAP against RFTAT with AL (standard of care) for reducing Plasmodium falciparum prevalence and incidence. METHODS/DESIGN: The study will be conducted in four districts in Southern Province, Zambia; an area of low malaria transmission and high coverage of vector control. A community randomized controlled trial of 16 health facility catchment areas will be used to evaluate the impact of sustained year-round routine RFDA for 2 years, relative to a control of year-round routine RFTAT. Reactive case detection will be triggered by a confirmed malaria case, e.g., by microscopy or rapid diagnostic test at any government health facility. Reactive responses will be performed by community health workers (CHW) within 7 days of the index case confirmation date. Responses will be performed out to a radius of 140 m from the index case household. A subset of responses will be followed longitudinally for 90 days to examine reinfection rates. Primary outcomes include a post-intervention survey of malaria seropositivity (n = 4800 children aged 1 month to under 5 years old) and a difference-in-differences analysis of malaria parasite incidence, as measured through routine passive case detection at health facilities enrolled in the study. The study is powered to detect approximately a 65% relative reduction in these outcomes between the intervention versus the control. DISCUSSION: Strengths of this trial include a robust study design and an endline cross-sectional parasite survey as well as a longitudinal sample. Primary limitations include statistical power to detect only a 65% reduction in primary outcomes, and the potential for contamination to dilute the effects of the intervention. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02654912 . Registered on 12 November 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bridges DJ, Miller JM, Chalwe V, et al. Community-led Responses for Elimination (CoRE): a study protocol for a community randomized controlled trial assessing the effectiveness of community-level, reactive focal drug administration for reducing Plasmodium falciparum infection prevalence and incidence in Southern Province, Zambia. Trials. 2017. PMID: 29096671. doi:10.1186/s13063-017-2249-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。